Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:immunotherapy
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2014
gptkb:FDA |
| gptkbp:atccode |
J05 AP05
|
| gptkbp:bioavailability |
approximately 67%
|
| gptkbp:can_be_combined_with |
gptkb:sofosbuvir
|
| gptkbp:casnumber |
1009114-65-1
|
| gptkbp:chemical_formula |
C22 H24 N6 O3 S
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
severe liver disease
|
| gptkbp:developed_by |
gptkb:Bristol-Myers_Squibb
|
| https://www.w3.org/2000/01/rdf-schema#label |
daclatasvir
|
| gptkbp:marketed_as |
gptkb:Daklinza
|
| gptkbp:mechanism_of_action |
NS5 A inhibitor
|
| gptkbp:side_effect |
gptkb:anemia
fatigue headache nausea insomnia |
| gptkbp:used_for |
treatment of hepatitis C
|
| gptkbp:bfsParent |
gptkb:sofosbuvir
|
| gptkbp:bfsLayer |
5
|